These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 36322404)

  • 21. A pilot feasibility study of an unguided, internet-delivered cognitive behavioral therapy program for irritable bowel syndrome.
    Owusu JT; Sibelli A; Moss-Morris R; van Tilburg MAL; Levy RL; Oser M
    Neurogastroenterol Motil; 2021 Nov; 33(11):e14108. PubMed ID: 33745228
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hypnotherapy for Irritable Bowel Syndrome-Type Symptoms in Patients with Quiescent Inflammatory Bowel Disease: A Randomized, Controlled Trial.
    Hoekman DR; Vlieger AM; Stokkers PC; Mahhmod N; Rietdijk S; de Boer NK; de Meij TG; Frankenhuis C; D'Haens GR; Benninga MA
    J Crohns Colitis; 2021 Jul; 15(7):1106-1113. PubMed ID: 33245332
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The prevalence of irritable bowel syndrome-type symptoms in inflammatory bowel disease patients in remission.
    Hoekman DR; Zeevenhooven J; D'Haens GR; Benninga MA
    Eur J Gastroenterol Hepatol; 2017 Sep; 29(9):1086-1090. PubMed ID: 28639969
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of a prodromal period in Crohn's disease but not ulcerative colitis.
    Pimentel M; Chang M; Chow EJ; Tabibzadeh S; Kirit-Kiriak V; Targan SR; Lin HC
    Am J Gastroenterol; 2000 Dec; 95(12):3458-62. PubMed ID: 11151877
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Self-administered cognitive behavior therapy for moderate to severe irritable bowel syndrome: clinical efficacy, tolerability, feasibility.
    Lackner JM; Jaccard J; Krasner SS; Katz LA; Gudleski GD; Holroyd K
    Clin Gastroenterol Hepatol; 2008 Aug; 6(8):899-906. PubMed ID: 18524691
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Screening irritable bowel syndrome patients for symptoms predictive of crohn's disease using the red flag score.
    Mosli M; Bamarhul M; Alharbi A; Shafei S; Alharbi A; Bamahfouth K; Jawa H; Aljahdali E; Bazaraa S; Qari Y
    Saudi J Gastroenterol; 2017; 23(4):229-232. PubMed ID: 28721976
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anhedonia in irritable bowel syndrome and in inflammatory bowel diseases and its relationship with abdominal pain.
    Carpinelli L; Bucci C; Santonicola A; Zingone F; Ciacci C; Iovino P
    Neurogastroenterol Motil; 2019 Mar; 31(3):e13531. PubMed ID: 30628137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.
    Fairbrass KM; Costantino SJ; Gracie DJ; Ford AC
    Lancet Gastroenterol Hepatol; 2020 Dec; 5(12):1053-1062. PubMed ID: 33010814
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The visceral sensitivity index: A novel tool for measuring GI-symptom-specific anxiety in inflammatory bowel disease.
    Trieschmann K; Chang L; Park S; Naliboff B; Joshi S; Labus JS; Sauk JS; Limketkai BN; Mayer EA
    Neurogastroenterol Motil; 2022 Sep; 34(9):e14384. PubMed ID: 35478469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tricyclic antidepressants for management of residual symptoms in inflammatory bowel disease.
    Iskandar HN; Cassell B; Kanuri N; Gyawali CP; Gutierrez A; Dassopoulos T; Ciorba MA; Sayuk GS
    J Clin Gastroenterol; 2014; 48(5):423-9. PubMed ID: 24406434
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prevalence of irritable bowel syndrome-like symptoms using Rome IV criteria in patients with inactive inflammatory bowel disease and relation with quality of life.
    Ozer M; Bengi G; Colak R; Cengiz O; Akpinar H
    Medicine (Baltimore); 2020 May; 99(19):e20067. PubMed ID: 32384473
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Popular diets and nutritional assessment in the management of irritable bowel syndrome in inflammatory bowel disease: an overview of current evidence.
    Covello C; Becherucci G; Scaldaferri F; Laterza L; Gasbarrini A; Mentella MC
    Pol Arch Intern Med; 2024 Feb; 134(2):. PubMed ID: 38226581
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biofeedback for treatment of irritable bowel syndrome.
    Goldenberg JZ; Brignall M; Hamilton M; Beardsley J; Batson RD; Hawrelak J; Lichtenstein B; Johnston BC
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31713856
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Lower gastric sensitivity in quiescent inflammatory bowel disease than in irritable bowel syndrome.
    Schulz A; Welsch SK; Etringer S; Hansen G; Milbert L; Schneider J; Taddei G; Gomez Bravo R; Lygidakis C; van Dyck Z; Lutz A; Wilmes P; Vögele C
    Physiol Behav; 2023 Oct; 270():114293. PubMed ID: 37468056
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Blastocystosis in patients with gastrointestinal symptoms: a case-control study.
    Cekin AH; Cekin Y; Adakan Y; Tasdemir E; Koclar FG; Yolcular BO
    BMC Gastroenterol; 2012 Sep; 12():122. PubMed ID: 22963003
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Homeopathy for treatment of irritable bowel syndrome.
    Peckham EJ; Cooper K; Roberts ER; Agrawal A; Brabyn S; Tew G
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD009710. PubMed ID: 31483486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Genomic and clinical effects associated with a relaxation response mind-body intervention in patients with irritable bowel syndrome and inflammatory bowel disease.
    Kuo B; Bhasin M; Jacquart J; Scult MA; Slipp L; Riklin EI; Lepoutre V; Comosa N; Norton BA; Dassatti A; Rosenblum J; Thurler AH; Surjanhata BC; Hasheminejad NN; Kagan L; Slawsby E; Rao SR; Macklin EA; Fricchione GL; Benson H; Libermann TA; Korzenik J; Denninger JW
    PLoS One; 2015; 10(4):e0123861. PubMed ID: 25927528
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A comparison of self-perceived health status in inflammatory bowel disease and irritable bowel syndrome patients from a Canadian national population survey.
    Tang LY; Nabalamba A; Graff LA; Bernstein CN
    Can J Gastroenterol; 2008 May; 22(5):475-83. PubMed ID: 18478133
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Multigene analysis can discriminate between ulcerative colitis, Crohn's disease, and irritable bowel syndrome.
    von Stein P; Lofberg R; Kuznetsov NV; Gielen AW; Persson JO; Sundberg R; Hellstrom K; Eriksson A; Befrits R; Ost A; von Stein OD
    Gastroenterology; 2008 Jun; 134(7):1869-81; quiz 2153-4. PubMed ID: 18466904
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Faecal calprotectin testing for differentiating amongst inflammatory and non-inflammatory bowel diseases: systematic review and economic evaluation.
    Waugh N; Cummins E; Royle P; Kandala NB; Shyangdan D; Arasaradnam R; Clar C; Johnston R
    Health Technol Assess; 2013 Nov; 17(55):xv-xix, 1-211. PubMed ID: 24286461
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.